Navigation Links
Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™
Date:2/15/2011

uorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com.

Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 18 molecules to market and has  many  years  of  experience  in  multiple  molecule  classes  such  as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products
'/>"/>

SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
2. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
3. Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
6. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
7. Boehringer Ingelheim Unveils Diabetes Pipeline
8. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
9. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
10. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
11. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... June 3, 2007 - Schering-Plough Corp. announced ... maintenance chemotherapy with,Caelyx (pegylated liposomal doxorubicin hydrochloride),significantly ... with,metastatic breast cancer with infrequent and manageable ... presented,today at the 43rd Annual Meeting of ...
... of Largest Ever Phase III Clinical Trial ... /PRNewswire-FirstCall/ --,GlaxoSmithKline today announced final results of ... investigational MAGE-A3,Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3,positive ... Cell Lung Cancer,(NSCLC). These data were presented ...
Cached Medicine Technology:Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 2Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 3Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 4Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 6
(Date:9/30/2014)... A new study of 58 ... impact of stress on metabolism after eating a high-fat meal ... a fast food restaurant, about 930 calories and 60 grams ... minutes every hour for 7 hours, conducting the study twice ... had experienced a stressful event in their lives during the ...
(Date:9/30/2014)... granted new patient appointments to Medicaid beneficiaries and ... care practices (non-FQHCs), in addition to charging less ... 10-state University of Pennsylvania study published this month ... from a previous "secret shopper" study conducted in ... community health clinics that receive federal funding ...
(Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... certified nutrition specialist and best-selling author Mike Geary that is ... totally transform their body into a fat-burning machine in less ... prompting an investigative review. , “In our culture that ... can be hard to decipher what is really fact and ...
(Date:9/30/2014)... VisitandCare.com reports that revenue for ... more than 79 percent in 2014, marking five straight ... total revenue tripled for its entirety of partnered medical ... has allowed them to partner with plastic surgery ... and privacy — with state-of-the-art surgical atmospheres aimed to ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... cancer patients of reproductive age, radiation treatment directly to ... direct relationship between certain types of radiation therapy and ... 1 issue of the International Journal of Radiation ... for Radiation Oncology (ASTRO). , Radiation therapy to ...
... with schizoaffective disorder who received paliperidone extended release ... improvement in a broad range of schizoaffective symptoms, ... the 12th International Congress on Schizophrenia Research (ICOSR) ... study provide additional evidence for symptomatic improvement of ...
... Federally Employed Women (FEW) salutes the House ... included two very important federal worker provisions. An ... Stephen Lynch (D-9-MA) to include the Federal Employees ... legislation during a previous mark up of the ...
... researchers say it,s not clear if one causes the ... research provides more evidence of a link between sleeplessness ... whether insomnia actually makes people want to kill themselves. ... problems might be an important contributor to suicidal thinking," ...
... release is available in Spanish . ... study of working memory. In terms of information retention, ... affected in diseases such as Alzheimer, and short-term or ... or structure a discourse. This more ephemeral memory is ...
... of Children and Adults Living with Autism , ... ... non-profit provider of autism services, Easter Seals believes every ... to a continuum of appropriate autism resources and receive necessary services, ...
Cached Medicine News:Health News:Some radiation therapy treatments can decrease fertility 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 7Health News:FEW Salutes House for Passing Legislation with Federal Worker Provisions; FERS Sick Leave Credit and FERS Redeposit Approved 2Health News:FEW Salutes House for Passing Legislation with Federal Worker Provisions; FERS Sick Leave Credit and FERS Redeposit Approved 3Health News:Insomnia Linked to Suicidal Thoughts, Attempts 2Health News:Insomnia Linked to Suicidal Thoughts, Attempts 3Health News:Activation of the prefrontal cortex improves working memory 2Health News:The Time to Act for Families is Now -- Will You Act For Autism with Easter Seals? 2Health News:The Time to Act for Families is Now -- Will You Act For Autism with Easter Seals? 3Health News:The Time to Act for Families is Now -- Will You Act For Autism with Easter Seals? 4
6 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm, 1 x 2. Orientation: Left hand....
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish....
Stainless steel model of the popular Nordan titanium Colibri forceps. Tying platform with 0.12 mm teeth for grasping delicate structures. Flattened round handle with polished finish....
0.12 mm, 1 x 2 teeth set at 45 degrees with 4.5 mm tying platform. Serrated handle with polished finish....
Medicine Products: